A new study using human pluripotent stem cell (hPSC)-derived human pancreatic organoids to model neoplastic transformation and cancer-derived human pancreatic tumor organoids for drug testing provides new personalized approaches to modeling and treating this malignancy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers
Biomarker Research Open Access 08 October 2022
-
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
Experimental Hematology & Oncology Open Access 05 December 2018
-
Organoid technology and applications in cancer research
Journal of Hematology & Oncology Open Access 15 September 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sato, T. et al. Nature 459, 262–265 (2009).
Spence, J.R. et al. Nature 470, 105–109 (2011).
Boj, S.F. et al. Cell 160, 324–338 (2015).
van de Wetering, M. et al. Cell 161, 933–945 (2015).
Ootani, A. et al. Nat. Med. 15, 701–706 (2009).
Huang, L. et al. Nat. Med. 21, 1364–1371 (2015).
Nostro, M.C. et al. Stem Cell Rep. 4, 591–604 (2015).
Matano, M. et al. Nat. Med. 21, 256–262 (2015).
Li, X. et al. Nat. Med. 20, 769–777 (2014).
Drost, J. et al. Nature 521, 43–47 (2015).
Gao, D. et al. Cell 159, 176–187 (2014).
Crystal, A.S. et al. Science 346, 1480–1486 (2014).
Kurian, A.W. Curr. Opin. Obstet. Gynecol. 22, 72–78 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.J.K. is an inventor on a pending patent describing organoid culture methodologies.
Rights and permissions
About this article
Cite this article
Zhang, H., Kuo, C. Personalizing pancreatic cancer organoids with hPSCs. Nat Med 21, 1249–1251 (2015). https://doi.org/10.1038/nm.3992
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3992
This article is cited by
-
The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers
Biomarker Research (2022)
-
The San Diego Nathan Shock Center: tackling the heterogeneity of aging
GeroScience (2021)
-
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
Experimental Hematology & Oncology (2018)
-
Organoid technology and applications in cancer research
Journal of Hematology & Oncology (2018)
-
Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients
Cancer Cell International (2017)